Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Update

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the target of a significant growth in short interest in September. As of September 30th, there was short interest totalling 48,300 shares, a growth of 182.5% from the September 15th total of 17,100 shares. Based on an average trading volume of 56,600 shares, the short-interest ratio is currently 0.9 days. Approximately 5.8% of the shares of the stock are sold short.

Phio Pharmaceuticals Price Performance

Shares of Phio Pharmaceuticals stock traded up $0.13 on Friday, hitting $2.68. The company had a trading volume of 19,574 shares, compared to its average volume of 38,614. The business has a 50-day simple moving average of $3.00 and a 200-day simple moving average of $4.94. The company has a market cap of $1.37 million, a PE ratio of -0.09 and a beta of 1.45. Phio Pharmaceuticals has a 52 week low of $2.40 and a 52 week high of $18.81.

Phio Pharmaceuticals (NASDAQ:PHIO) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($3.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.59) by $0.97.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.